184 related articles for article (PubMed ID: 36295829)
1. Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria.
Norman BP; Davison AS; Hickton B; Ross GA; Milan AM; Hughes AT; Wilson PJM; Sutherland H; Hughes JH; Roberts NB; Bou-Gharios G; Gallagher JA; Ranganath LR
Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295829
[TBL] [Abstract][Full Text] [Related]
2. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
[TBL] [Abstract][Full Text] [Related]
3. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
[TBL] [Abstract][Full Text] [Related]
5. Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.
Norman BP; Sutherland H; Wilson PJM; Rutland DA; Milan AM; Hughes AT; Davison AS; Khedr M; Jarvis JC; Gallagher JA; Bou-Gharios G; Ranganath LR
J Inherit Metab Dis; 2024 Mar; ():. PubMed ID: 38487984
[TBL] [Abstract][Full Text] [Related]
6. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
Ranganath LR; Milan AM; Hughes AT; Davison AS; M K; Norman BP; Bou-Gharios G; Gallagher JA; Imrich R; Arnoux JB; Rudebeck M; Olsson B
Sci Rep; 2022 Sep; 12(1):16083. PubMed ID: 36167967
[TBL] [Abstract][Full Text] [Related]
7. Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment.
Ranganath LR; Milan AM; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA
Metabolites; 2022 Aug; 12(8):. PubMed ID: 36005644
[TBL] [Abstract][Full Text] [Related]
8. Method development and validation for analysis of phenylalanine, 4-hydroxyphenyllactic acid and 4-hydroxyphenylpyruvic acid in serum and urine.
Hughes AT; Milan AM; Shweihdi E; Gallagher J; Ranganath L
JIMD Rep; 2022 Jul; 63(4):341-350. PubMed ID: 35822095
[TBL] [Abstract][Full Text] [Related]
9. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
[TBL] [Abstract][Full Text] [Related]
10. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
[TBL] [Abstract][Full Text] [Related]
11. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.
Olsson B; Cox TF; Psarelli EE; Szamosi J; Hughes AT; Milan AM; Hall AK; Rovensky J; Ranganath LR
JIMD Rep; 2015; 24():21-7. PubMed ID: 25772318
[TBL] [Abstract][Full Text] [Related]
13. Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.
Ranganath LR; Milan AM; Hughes AT; Khedr M; Norman BP; Alsbou M; Imrich R; Gornall M; Sireau N; Gallagher JA; Jackson R
JIMD Rep; 2022 Jan; 63(1):80-92. PubMed ID: 35028273
[TBL] [Abstract][Full Text] [Related]
14. Temporal adaptations in the phenylalanine/tyrosine pathway and related factors during nitisinone-induced tyrosinaemia in alkaptonuria.
Ranganath LR; Hughes AT; Davison AS; Khedr M; Olsson B; Rudebeck M; Imrich R; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
Mol Genet Metab; 2022 Jun; ():. PubMed ID: 35680516
[TBL] [Abstract][Full Text] [Related]
15. Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria.
Ranganath LR; Milan AM; Hughes AT; Davison AS; Khedr M; Norman BP; Bou-Gharios G; Gallagher JA; Gornall M; Jackson R; Imrich R; Rovensky J; Rudebeck M; Olsson B
Mol Genet Metab Rep; 2022 Mar; 30():100846. PubMed ID: 35242577
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
Ranganath LR; Psarelli EE; Arnoux JB; Braconi D; Briggs M; Bröijersén A; Loftus N; Bygott H; Cox TF; Davison AS; Dillon JP; Fisher M; FitzGerald R; Genovese F; Glasova H; Hall AK; Hughes AT; Hughes JH; Imrich R; Jarvis JC; Khedr M; Laan D; Le Quan Sang KH; Luangrath E; Lukáčová O; Milan AM; Mistry A; Mlynáriková V; Norman BP; Olsson B; Rhodes NP; Rovenský J; Rudebeck M; Santucci A; Shweihdi E; Scott C; Sedláková J; Sireau N; Stančík R; Szamosi J; Taylor S; van Kan C; Vinjamuri S; Vrtíková E; Webb C; West E; Záňová E; Zatkova A; Gallagher JA
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):762-772. PubMed ID: 32822600
[TBL] [Abstract][Full Text] [Related]
17. Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone.
Davison AS; Norman BP; Smith EA; Devine J; Usher J; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
JIMD Rep; 2018; 41():109-117. PubMed ID: 29754208
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS.
Davison AS; Norman BP; Ross GA; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
JIMD Rep; 2019 Jul; 48(1):67-74. PubMed ID: 31392115
[TBL] [Abstract][Full Text] [Related]
19. Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria.
Davison AS; Norman BP; Sutherland H; Milan AM; Gallagher JA; Jarvis JC; Ranganath LR
Metabolites; 2022 May; 12(6):. PubMed ID: 35736410
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Phenylalanine- and Tyrosine-Restricted Diet in Alkaptonuria Patients on Nitisinone Treatment: Case Series and Review of Literature.
Teke Kisa P; Eroglu Erkmen S; Bahceci H; Arslan Gulten Z; Aydogan A; Karalar Pekuz OK; Yuce Inel T; Ozturk T; Uysal S; Arslan N
Ann Nutr Metab; 2022; 78(1):48-60. PubMed ID: 34736252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
